These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The pharmacological efficacy of mycophenolic acid before and after renal transplantation as estimated by the lymphocyte immunosuppressant sensitivity test (LIST). Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T Immunopharmacol Immunotoxicol; 2010 Sep; 32(3):430-6. PubMed ID: 20095807 [TBL] [Abstract][Full Text] [Related]
3. Ex vivo lymphocyte proliferative function is severely inhibited in renal transplant patients on mycophenolate mofetil treatment. Hutchinson P; Jose M; Atkins RC; Holdsworth SR Transpl Immunol; 2004; 13(1):55-61. PubMed ID: 15203129 [TBL] [Abstract][Full Text] [Related]
4. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Allison AC; Eugui EM Clin Transplant; 1996 Feb; 10(1 Pt 2):77-84. PubMed ID: 8680053 [TBL] [Abstract][Full Text] [Related]
5. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients. Merkel U; Lindner S; Vollandt R; Sperschneider H; Balogh A Int J Clin Pharmacol Ther; 2005 Aug; 43(8):379-88. PubMed ID: 16119513 [TBL] [Abstract][Full Text] [Related]
6. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Staatz CE; Tett SE Arch Toxicol; 2014 Jul; 88(7):1351-89. PubMed ID: 24792322 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. Gummert JF; Barten MJ; Sherwood SW; van Gelder T; Morris RE J Pharmacol Exp Ther; 1999 Dec; 291(3):1100-12. PubMed ID: 10565830 [TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of mycophenolic acid in heart allograft recipients: correlation of lymphocyte proliferation and activation with pharmacokinetics and graft histology. Gummert JF; Barten MJ; van Gelder T; Billingham ME; Morris RE Transplantation; 2000 Oct; 70(7):1038-49. PubMed ID: 11045640 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Shaw LM; Korecka M; DeNofrio D; Brayman KL Clin Biochem; 2001 Feb; 34(1):17-22. PubMed ID: 11239510 [TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive efficacy of mycophenolate mofetil when compared with azathioprine and mizoribine against peripheral lymphocytes from renal transplant recipients. Sugiyama K; Satoh H; Saito K; Takahashi K; Saito N; Hirano T Transpl Int; 2005 May; 18(5):590-5. PubMed ID: 15819809 [TBL] [Abstract][Full Text] [Related]
11. Inosine 5'-Monophosphate Dehydrogenase Activity for the Longitudinal Monitoring of Mycophenolic Acid Treatment in Kidney Allograft Recipients. Glander P; Waiser J; Hambach P; Bachmann F; Budde K; Eckardt KU; Friedersdorff F; Gaedeke J; Kron S; Lorkowski C; Mai M; Neumayer HH; Peters R; Rudolph B; Schmidt D; Wu K; Liefeldt L Transplantation; 2021 Apr; 105(4):916-927. PubMed ID: 32496356 [TBL] [Abstract][Full Text] [Related]
12. Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen. Ohata K; Espinoza JL; Lu X; Kondo Y; Nakao S Biol Blood Marrow Transplant; 2011 Feb; 17(2):205-13. PubMed ID: 20736080 [TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil and its mechanisms of action. Allison AC; Eugui EM Immunopharmacology; 2000 May; 47(2-3):85-118. PubMed ID: 10878285 [TBL] [Abstract][Full Text] [Related]
14. In Vitro Influence of Mycophenolic Acid on Selected Parameters of Stimulated Peripheral Canine Lymphocytes. Guzera M; Szulc-Dąbrowska L; Cywińska A; Archer J; Winnicka A PLoS One; 2016; 11(5):e0154429. PubMed ID: 27138877 [TBL] [Abstract][Full Text] [Related]
15. Simultaneous quantification of IMPDH activity and purine bases in lymphocytes using LC-MS/MS: assessment of biomarker responses to mycophenolic acid. Vethe NT; Ali AM; Reine PA; Andersen AM; Bremer S; Line PD; Rootwelt H; Bergan S Ther Drug Monit; 2014 Feb; 36(1):108-18. PubMed ID: 24061448 [TBL] [Abstract][Full Text] [Related]
16. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Eugui EM; Almquist SJ; Muller CD; Allison AC Scand J Immunol; 1991 Feb; 33(2):161-73. PubMed ID: 1826793 [TBL] [Abstract][Full Text] [Related]
17. Mycophenolic Acid Trough Concentration and Dose Are Associated with Hematologic Abnormalities but Not Rejection in Kidney Transplant Recipients. Jung HY; Lee S; Jeon Y; Choi JY; Cho JH; Park SH; Kim YL; Kim HK; Huh S; Won DI; Kim CD J Korean Med Sci; 2020 Jun; 35(24):e185. PubMed ID: 32567256 [TBL] [Abstract][Full Text] [Related]
18. Monitoring of mycophenolic acid and kidney function during combined immunosuppressive therapy. Oláh AV; Asztalos L; Ivády G; Varga E; Kovács AM; Kappelmayer J; Varga J Clin Chem Lab Med; 2011 Nov; 49(11):1849-53. PubMed ID: 21848499 [TBL] [Abstract][Full Text] [Related]
19. In vitro effects of mycophenolic acid on cell cycle and activation of human lymphocytes. Heinschink A; Raab M; Daxecker H; Griesmacher A; Müller MM Clin Chim Acta; 2000 Oct; 300(1-2):23-8. PubMed ID: 10958860 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and Characterization of a Novel Mycophenolic Acid-Quinic Acid Conjugate Serving as Immunosuppressant with Decreased Toxicity. Peng Y; Dong Y; Mahato RI Mol Pharm; 2015 Dec; 12(12):4445-53. PubMed ID: 26529468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]